The effect of mildronate on carnitine-dependent and carnitine-independent ketogenesis in rats
Simkhovich, B.Z.; Meĭrena, D.V.; Khagi, K.B.; Shutenko, Z.V.; Molodchina, T.N.; Kalvin'sh, I.I.; Lukevits, E.I.
Farmakologiia i Toksikologiia 54(4): 41-42
1991
ISSN/ISBN: 0014-8318 PMID: 1786824 Document Number: 376524
Mildronate of 3-(2,2,2-trimethylhydrozinium)propionate, a novel anti-ischemic drug, inhibits the biosynthesis of carnitine from Y-butyrobetaine. Continuous administration of mildronate (200, 400 mg/kg for 10 days orally) to rats exerted a marked antiketogenic action on the animals deprived of food for 48 hours. In the fed rats receiving sodium octanoate a course treatment with mildronate elevated to concentration of ketone bodies in blood serum. Selective regulation of carnitine-independent and carnitine-dependent metabolism appears justified for the treatment of such pathological states as ischemic heart disease, diabetes and obesity.